Climb Bio’s Kidney Disease Therapy Gets Support for Extended Dosing Schedule
Climb Bio announced positive Phase 1 data for CLYM116 and outlined its strategy to advance the IgA nephropathy candidate into Phase 3.
Climb Bio's kidney medicine showed it could work well with patients taking it less often, which is good news for the company's plans. When a medicine needs fewer doses, doctors and patients like it better, so watch if the company keeps making progress toward final testing.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.